Common adverse effects of Ozempic, as documented in the UK SmPC, include: Gastrointestinal symptoms : nausea, vomiting, diarrhoea, constipation, abdominal pain (very common, affecting more than 1 in 10 patients) Decreased appetite (very common) Hypoglycaemia : when used in combination with insulin or sulphonylureas Gallbladder disorders : including cholelithiasis and cholecystitis Fatigue Injection site reactions : such as bruising or pain Whilst musculoskeletal pain is not formally listed, healthcare professionals should remain vigilant for patient reports and consider the broader context of treatment, including weight loss trajectory, nutritional status, and concurrent medical conditions
SEMAGLUTIDE We have identified that Novo Nordisk has filed 320 U.S
In perimenopause, the years leading up to menopause, cycles may become shorter, longer, or irregular due to hormonal fluctuations
As a non-peptide compound that is chemically stable in acidic conditions and resistant to enzymatic degradation, orforglipron does not depend on the gastric environment or specific absorption-enhancing conditions for its oral uptake
ALT ratios (95%CI) at week 52 in those with high baseline ALT were: 0.88 (0.76-1.01
In the SURMOUNT-1 trial, participants lost between 16% and 22.5% of their body weight depending on dose, results that raised the bar for what many believed was possible with medication-assisted weight loss